Myelofibrosis secondary to renal osteodystrophy

Area of Science:

• Nephrology
• Endocrinology
• Hematology

Background:

• Secondary hyperparathyroidism is a common complication in patients with end-stage renal disease undergoing hemodialysis.
• Myelofibrosis, a serious bone marrow disorder, can be associated with severe secondary hyperparathyroidism.
• Recombinant human erythropoietin (rhEpo) therapy and transfusions are often required to manage anemia in these patients.

Observation:

• A hemodialyzed patient with secondary hyperparathyroidism presented with myelofibrosis, splenomegaly, and leukoerythroblastosis.
• The patient required regular transfusions and rhEpo therapy to maintain adequate hematocrit.
• Diagnosis was confirmed by bone marrow biopsy and scintigraphy.

Findings:

• Following total parathyroidectomy with forearm autotransplantation (PTx), the patient's hematocrit gradually increased without transfusions, stabilizing at 35% over 16 months.
• Splenomegaly regressed, and leukoerythroblastosis resolved.
• Bone marrow scintigraphy showed a decline in extramedullary hematopoiesis, indicating reversal of myelofibrosis.

Implications:

• This case suggests that myelofibrosis in the context of secondary hyperparathyroidism may be a potentially reversible complication.
• Accurate treatment of secondary hyperparathyroidism can lead to significant hematological improvement in affected patients.
• Nephrologists and endocrinologists should consider this association and monitor for myelofibrosis in patients with severe secondary hyperparathyroidism.